Welcome to our dedicated page for Predictive Oncology SEC filings (Ticker: POAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding Predictive Oncology’s SEC disclosures can feel like running a clinical trial of your own—hundreds of pages on AI-driven drug screens, biobank valuations, and FDA-regulated devices. Whether you’re tracking STREAMWAY revenue or the PEDAL platform’s impact on R&D spend, the details hide deep inside 10-K footnotes and 8-K exhibits.
Stock Titan solves that problem. Our AI-powered summaries translate each Predictive Oncology annual report 10-K simplified, every quarterly earnings report 10-Q filing, and each Predictive Oncology 8-K material events explained into clear, actionable language. Need real-time alerts? We surface Predictive Oncology Form 4 insider transactions in real time, flagging executive stock sales before they hit the news. The platform covers the full spectrum—proxy statement executive compensation tables, registration statements, and even niche S-8 filings—updated the minute EDGAR posts.
Looking for specific answers? Use our search prompts like “understanding Predictive Oncology SEC documents with AI” or “Predictive Oncology earnings report filing analysis” and jump straight to AI-generated highlights: segment revenue trends, cash runway projections, and risk-factor changes. Monitor Predictive Oncology insider trading Form 4 transactions, compare R&D outlays quarter-over-quarter, or download clean tables for your own models. With comprehensive filing coverage, plain-English explanations, and machine-learning insights, Stock Titan turns complex biotech disclosures into practical intelligence investors actually use.
Predictive Oncology Inc. filed a resale registration covering up to 5,970,181 shares of common stock, to be sold from time to time by the selling stockholders after effectiveness. The company is not offering any shares.
The registered amount includes 3,365,690 PIPE Shares issued in August and September private placements, plus 2,604,491 shares issuable upon warrant exercise, consisting of 1,037,250 Cash PIPE Warrant Shares, 218,335 Agent Warrant Shares, and 1,348,906 Advisor Warrant Shares.
No proceeds will go to the company from stockholder resales. The company would receive cash only upon warrant exercises. The Cash PIPE Warrants carry a nominal $0.01 per-share exercise price; Agent and Advisor Warrants are exercisable at $11.6265 per share. POAI trades on Nasdaq; the last reported price was $9.30 per share on October 21, 2025.
Predictive Oncology Inc. filed a resale registration covering up to 14,903,393 shares of common stock underlying pre-funded warrants issued under a September 29, 2025 securities purchase agreement. The shares may be sold from time to time by the selling stockholders named in the prospectus.
The company is not offering any shares and will not receive proceeds from sales by the selling stockholders; it would receive only any cash paid upon warrant exercise. The warrants carry a $0.01 per share exercise price, have no expiration, and include a 19.99% beneficial ownership limitation. Exercise of these warrants is subject to shareholder approval for the underlying share issuance.
As context, the company’s Nasdaq ticker is POAI, and the last reported sale price was $9.30 per share on October 21, 2025. The filing notes a recent 1-for-15 reverse stock split effective September 30, 2025, and outlines a separate cash PIPE and a crypto-funded PIPE that introduced these pre-funded warrants. The plan of distribution permits various sale methods by the selling holders.
Predictive Oncology Inc. (POAI) filed a Form 3 for a director, the initial statement of beneficial ownership under Section 16. The filing states no securities are beneficially owned as of the event date 10/07/2025. The submission includes an Exhibit 24.1 Power of Attorney, and was signed by Josh Blacher, Attorney-in-Fact. This is an administrative disclosure and does not reflect a transaction.
Predictive Oncology (POAI)no securities are beneficially owned as of the event date 10/08/2025.
The filing includes Exhibit 24.1, a Power of Attorney, and was submitted as a single‑person filing.
Predictive Oncology set its 2025 annual meeting for November 25, 2025, in Pittsburgh at DLA Piper LLP (US). Stockholders of record on October 24, 2025 will be entitled to vote.
Stockholder proposals and proxy access requests must be received by October 26, 2025. The company expects to mail definitive proxy materials on or about November 3, 2025 and may supplement those materials, and if necessary postpone the meeting, to address any timely proposals.
Predictive Oncology Inc. disclosed material transactions tied to private placements that include cash and cryptocurrency investments subject to customary closing conditions. The company agreed to issue placement agent warrants to purchase approximately 3.3 million shares exercisable at $0.7751 for five years and to pay a 5% cash fee to the placement agent for gross cash proceeds (excluding digital-asset proceeds). Strategic advisor warrants equal to approximately 20.3 million shares (about 7% of the securities sold) will be issued, exercisable at $0.7751 for five years and carrying a beneficial ownership cap of 4.99% (or optionally 9.99%). A Side Letter with DCI Foundation requires DCI to cure issues with locked crypto within five business days and to deliver an additional 20% of ATH tokens bought on the open market within 30 days of each purchase. The company amended bylaws effective September 26, 2025 to cap the board at seven directors. Various form agreements and exhibits were filed.
Predictive Oncology, Inc. filed a Form 8-K reporting a material event that includes a Certificate of Amendment to its certificate of incorporation and an attached press release dated
Predictive Oncology director Nancy Chung-Welch received a grant of 64,680 restricted stock units (RSUs) on 09/09/2025. Each RSU converts to one share of common stock upon vesting and the award vests in full on October 31, 2025, subject to continued service through that date. The transaction is reported as an acquisition at a $0.00 price, leaving Ms. Chung-Welch with 83,993 shares beneficially owned after the grant.
FAQ
What is the current stock price of Predictive Oncology (POAI)?
What is the market cap of Predictive Oncology (POAI)?
